Morgan Stanley Maintains Equal-Weight on Bowhead Specialty Hldgs, Raises Price Target to $34
Morgan Stanley analyst Bob Huang maintains Bowhead Specialty Hldgs (NYSE:BOW) with a Equal-Weight and raises the price target from $30 to $34.
Stocks · News reference
8-K filing — Bowhead Specialty Holdings Inc. (BOW)
Filed: 2026-08-19 AccNo: 0001628280-26-057976 Size: 141 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Downgrades Bowhead Specialty Hldgs to Sector Perform, Lowers Price Target to $34
RBC Capital analyst Rowland Mayor downgrades Bowhead Specialty Hldgs (NYSE:BOW) from Outperform to Sector Perform and lowers the price target from $38 to $34.
Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating three major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations involve Supernus Pharmaceuticals' sale to Indivior, Integer Holdings' acquisition by KKR, and Bowhead Specialty Holdings' sale to American Family Mutual Insurance. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.